MedTrace Logo

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

NCT02655757 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-01-25

No results posted yet for this study

Summary

This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on Progression of Coronary Intermediate Lesion.

Conditions

Interventions

DRUG

Sitagliptin

5 mg, 1 tablet per day for 12 months

DRUG

Placebo

Placebo,1 tablet per day for 12 months

Sponsors & Collaborators

  • Li Bo

    lead OTHER

Principal Investigators

  • Chen yundai, MD · The General Hospital of PLA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-02-02
Completion
2017-03-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02655757 on ClinicalTrials.gov